Send to a Friend Font Size: Increase Decrease

SPRO and IVBIY Related Headlines

Jul 14, 2026 06:00AM Spero Therapeutics licenses Innovent antibody in deal worth up to $1.1B
Jul 14, 2026 06:00AM Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

SPRO and IVBIY Related Press Releases

Jul 14, 2026 06:00AM Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

SPRO and IVBIY Related SEC Filings